Breast cancer

21 April 2010

New Guidelines Issued on Hormone Receptor Testing for Breast Cancer

Up to 20% of current results may be inaccurate, study says


This article has not necessarily been edited by Health24.

TUESDAY, April 20 (HealthDay News) -- The American Society of Clinical Oncology and the College of American Pathologists have issued new guidelines to improve the accuracy of the testing of estrogen and progesterone receptors in breast cancer patients.

The growth of as many as two-thirds of breast cancers are thought to be affected by the action of the estrogen-receptor pathway.

Estrogen (ER) and progesterone receptor (PgR) testing allows doctors to determine whether a patient's breast cancer fits into that group. In that case, the patient may be eligible to be treated with so-called endrocrine therapies -- including the drug tamoxifen -- that can improve survival.

But there's a problem: Worldwide, as many as 10 percent to 20 percent of these screens, known as immunohistochemistry tests, may be wrong.

"There is clearly a need to accurately identify breast cancer subtypes as ER- and/or PgR-positive to help us identify those patients most likely to benefit from endocrine therapy and minimize the risk of potentially denying effective and lifesaving therapy to patients incorrectly labeled as having ER/PgR-negative invasive disease, while allowing patients with true ER/PgR-negative disease to be considered for other therapies," Dr. Antonio C. Wolff, co-chair of a joint panel on hormone receptor testing in breast cancer and a professor of oncology at Johns Hopkins Kimmel Cancer Center in Baltimore, said in a news release.

Among a long list of recommendations, the guidelines encourage regular testing in newly diagnosed invasive breast cancers, uniform testing procedures and validation of tests.

The new guidelines were published April 19 in the Journal of Clinical Oncology and the Archives of Pathology & Laboratory Medicine.

More information

For more on breast cancer, see the U.S. National Library of Medicine.


Read Health24’s Comments Policy

Comment on this story
Comments have been closed for this article.

Ask the Expert

Breast cancer expert

Dr Gudgeon qualified in Birmingham, England, in 1968. She has more than 40 years experience in oncology, and in 1994 she founded her practice, Cape Breast Care, where she treats benign and malignant breast cancers. Dr Boeddinghaus obtained her qualification at UCT Medical School in 1994 and her MRCP in London in 1998. She has worked extensively in the field of oncology and has a special interest in the hormonal management of breast cancer. She now works with Dr Gudgeon at Cape Breast Care. Read more.

Still have a question?

Get free advice from our panel of experts

The information provided does not constitute a diagnosis of your condition. You should consult a medical practitioner or other appropriate health care professional for a physical exmanication, diagnosis and formal advice. Health24 and the expert accept no responsibility or liability for any damage or personal harm you may suffer resulting from making use of this content.

* You must accept our condition

Forum Rules